Participating Companies

Alligator Bioscience [ATORX:ST] SKr1,770 MM MCap
The com­pany spe­cial­izes in the de­vel­op­ment of tu­mor-di­rect­ed im­munother­a­pies, in par­tic­u­lar ag­on­is­tic mono- and bis­pe­cif­ic anti­bodies. In im­munother­a­py, the pa­tients´ im­mune sys­tem is ac­ti­vat­ed to cure can­cer. The term tu­mor-di­rect­ed means that the drug is ad­min­is­tered or de­signed such that the phar­ma­co­log­i­cal ef­fect is lo­cal­ized to the tu­mor. [more in­for­ma­tion]
Bone Therapeutics SA [BT1:FF] €38 MM MCap
Bone Ther­a­peu­tics is a biotech­nol­o­gy com­pany with a unique ap­proach to the de­vel­op­ment of cell ther­a­py prod­ucts for bone frac­ture re­pair and frac­ture pre­ven­tion. Bone Ther­a­peu­tics' tech­nol­o­gy is based on a unique, pro­pri­e­tary ap­proach to bone re­gen­er­a­tion which turns un­d­if­fer­en­ti­at­ed stem cells in­to “os­teoblas­tic”, or bone-form­ing cells. [more in­for­ma­tion]
Carisma Therapeutics Inc.
Pi­oneer­ing the de­vel­op­ment of CAR macrophages, a dis­rup­tive ap­proach to im­munother­a­py. The tech­nol­o­gy lev­er­ages ad­vances in macrophage bi­ol­o­gy, chimer­ic anti­gen re­cep­tor en­gi­neer­ing and adop­tive cel­lu­lar ther­a­py for the treat­ment of hu­man dis­ease. [more in­for­ma­tion]
CureVac AG
Found­ing Co of mR­NA space (last round $1bn+). In­tra­tu­mo­ral ther­a­py Ph1 (mul­ti­ple onc in­di­ca­tions) ini­ti­at­ed Q4 17, ear­ly da­ta rep at SITC. First pt en­rolled Ph 1 pro­phy­lac­tic mR­NA ra­bies vax Oct 2018. Pro­phy­lac­tic in­fluen­za vax ini­ti­a­tion Ph 1 2020, OTC de­fi­cien­cy Ph 1 ini­ti­a­tion H219. In­ter­im da­ta /all trials: 2019. [more in­for­ma­tion]
Hookipa Biotech [HOOK] US$192 MM MCap
is a clin­i­cal stage com­pany de­vel­op­ing prod­ucts to pre­vent and cure in­fec­tious dis­eas­es and can­cer. With this goal in mind we cre­at­ed unique and cutt­ing-edge tech­nolo­gies which re­pro­gram and sti­m­u­late the im­mune sys­tem. We are build­ing a pro­pri­e­tary im­mune-on­col­o­gy pipe­line by tar­get­ing Ther­aT® to­wards HPV+ head and neck squa­mous cell car­ci­no­ma and pros­tate can­cer. [more in­for­ma­tion]
The com­pany raised $9 mil­lion of grant fund­ing from Bill & Melin­da Gates Foun­da­tion on Jan­uary 9, 2017. The com­pany will use the fund­ing to strengthen its work to de­vel­op treat­ments and vaccines for in­fec­tious dis­ease us­ing its anti­body plat­form. [more in­for­ma­tion]
Mabion SA [0QGW.L]
The Com­pany’s pro­ject of the most pri­or­i­ty is the in­tro­duc­tion to mar­ket the Mabion­CD20 drug, biosim­i­lar medicine to MabThera (Ri­t­ux­imab). The ther­a­peu­tic in­di­ca­tions for the drug are for Non-Hodgkin’s lym­pho­ma, Leukemia and Rheu­ma­toid Arthri­tis (RA). [more in­for­ma­tion]
Medivir AB [MVIR B:ST] SKr936 MM MCap
Me­di­vir is a phar­ma­ceu­ti­cal com­pany fo­cus­ing on the de­vel­op­ment and com­mer­cial­iza­tion of in­no­va­tive treat­ments for can­cer. To do this ef­fi­cient­ly and with a high suc­cess rate, Me­di­vir brings to­gether a unique com­bi­na­tion of clin­i­cal de­vel­op­ment skills, a col­lab­o­ra­tive cul­ture and an ex­ten­sive in­dus­try ex­pe­ri­ence, with a bal­anced pro­ject port­fo­lio. [more in­for­ma­tion]
Nanobiotix SA [NANO:PA] €211 MM MCap
Nano­bi­otix is a lead­ing, clin­i­cal-stage nanomedicine com­pany pi­oneer­ing new ap­proach­es to sig­ni­f­i­cant­ly change pa­tient out­comes by bring­ing nano­physics to the heart of the cell. Nano­bi­otix’s Im­muno-On­col­o­gy pro­gram has the po­ten­tial to bring a new di­men­sion to can­cer im­munother­a­pies. [more in­for­ma­tion]
De­vel­op­ing first Glx tar­get­ed an­tide­pres­sant to ad­dress sui­ci­dal­i­ty in bipo­lar de­pres­sion. Lead can­di­date, NRX-101 in Ph 2b/3 de­vt (Break­thru Desig­na­tion, SPA and Fast Track Desig­na­tion by FDA) for Se­vere Bipo­lar De­pres­sion in pts w Acute Sui­ci­dal Idea­tion and Be­havior. Plans to pre­sent Ph 2 POC da­ta lat­er this year. [more in­for­ma­tion]
Nicox [COX:PA] €144 MM MCap
An in­ter­na­tio­n­al oph­thalmic R&D com­pany, aim­ing to build a di­ver­si­fied port­fo­lio of ther­a­peu­tic prod­ucts ad­dress­ing the needs of eye­care prac­ti­tion­ers and pa­tients around the world. [more in­for­ma­tion]
Oryzon Genomics [ORY:MA]
Tar­get­ing ly­sine spe­cif­ic demethy­lase 1 (LS­D1, aka KD­M1A). Lead CNS com­pound in 3 Phase 2a trials in MS, AD and bas­ket trial. Onc com­pound in 2 com­bo Phase 2a trials in AML and SCLC. Da­ta exp mid-2019 [more in­for­ma­tion]
Remi­ma­zo­lam: short-act­ing anes­thet­ic. Ph 3 study in pro­ce­du­ral se­da­tion in US. Safe­ty da­ta in ASA III/IV pa­tients in Ph 3 colonos­copy study and Ph 3 bron­chos­copy study. US ap­pro­val filed by part­n­er Cos­mo Phar­ma­ceu­ti­cals in June 2019. Ini­ti­at­ed Ph 3 in gen­er­al anes­th­e­sia in EU in Ju­ly 2018, exp com­ple­tion 2019. [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €497 MM MCap
On­ly prod­uct with fu­ture po­ten­tial to be ap­proved for both pro­phy­laxis and treat­ment of at­tacks of HAE. An­nounced pos­i­tive re­sults from a ph2 study of RU­CON­EST in Con­tract-in­duced Nephro­pa­thy for pa­tients re­ceiv­ing elec­tive coro­nary an­giog­ra­phy with or with­out a per­cu­ta­neous coro­nary in­ter­ven­tion (PCI). [more in­for­ma­tion]
Poxel SA [POXEL:PA] €167 MM MCap
Imeglimin (mi­to­chon­dria-based MOA) for T2D be­gan Ph 3 in Ja­pan with Asian part­n­er Su­m­i­t­o­mo Dainip­pon. Com­ple­tion of Phase 3 on track for 2019 and JN­DA sub­mis­sion in 2020. In 1Q18, an­nounced agree­ment w Roi­vant for Imeglimin (Ph 3 ready) in US, EU, and ad­dl coun­tries WW. [more in­for­ma­tion]
PsiOxus Therapeutics
The ther­a­py (NG-348), us­es virus to tran­s­port two ther­a­peu­tic genes di­rect­ly in­to tu­mors to re­cruit im­mune cells in­to at­tack­ing tar­get­ed can­cer cells. Up­com­ing Mile­s­tones: - 2 pro­grams in clin­ic with read­outs in 2019 (ovarian can­cer in comb w Pa­cl­i­tax­el, car­ci­no­mas in comb w nivolumab) - 2 INDs in 2018 (NG-348 and NG-350A) - 2 INDs in 2019 (NG-641 and NG-347) [more in­for­ma­tion]
San­i­fit is a bio­phar­ma­ceu­ti­cal com­pany fo­cused on treat­ments for cal­ci­fi­ca­tion di­s­or­ders, with SN­F472 as the lead com­pound. The com­pany is plan­n­ing to ini­ti­ate a phase III study in this or­phan dis­ease in 2018. The on­go­ing phase IIb study (Calip­so) in ES­RD pa­tients on dial­y­sis is eval­u­at­ing the ef­fect of SN­F472 on pro­gres­sion of ar­te­rial cal­ci­fi­ca­tion. [more in­for­ma­tion]
Targovax [TRVX:OS] NKr409 MM MCap
Tar­go­v­ax is a clin­i­cal stage biotech­nol­o­gy com­pany de­vel­op­ing im­mune ac­ti­va­tors to tar­get hard-to-treat solid tu­mors. Tar­go­v­ax’s lead prod­uct can­di­date, ON­COS-102, is a ge­net­i­cal­ly mod­i­fied on­co­lyt­ic ade­n­ovirus that has been en­gi­neered to se­lec­tive­ly in­fect and re­pli­cate in can­cer cells. It has been shown to ac­ti­vate the im­mune sys­tem to gen­er­ate tu­mor-spe­cif­ic im­mune re­spons­es. [more in­for­ma­tion]